• Letter or Testimony
  • May 25, 2016

340B Coalition Submits Comments on 340B Drug Pricing Program

CHA joined the other members of the 340B Coalition and submitted supplemental comments to HRSA's proposed rule, "340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation." HRSA originally released the proposed rule in 2015. Earlier this year, HRSA reopened the comment period on the proposed rule and specifically sought comments on three areas:

  1. HRSA's penny pricing policy for ceiling prices that are less than $0.01 
  2. Estimation of ceiling prices for new drugs 
  3. Definition of "knowing and intentional" for purposes of manufacturer civil monetary policies
CHA contact: Liz Parry, (202) 753-5392